Skip to main content

Advertisement

Table 4 Category 3 AMD cases undergoing genetic testing: baseline vision in neovascular AMD eyes in clinical practice integrated with MARINA trial presenting percentages

From: A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration

Model n % of baseline patients [18, 20]a Mean vision % with initial vision 20/40–20/80 % with initial vision ≤20/160
A. 1st eye 50 53.6 20/182 18 78.0
B. 2nd eye 98 46.4 20/84 37 62.2
Both eyes (A × B) 148 100.0 20/136 6.7 48.5
C. Sensitivity of genetic testing 148 90 NA A × B × C = 6.0 % A × B × C = 43.7 %
  1. AMD age-related macular degeneration, NA not applicable
  2. aMARINA (Minimally classic/occult trial of the Anti-VEGF antibody Ranibizumab In the treatment of Neovascular AMD) clinical trial [18, 20]